Itch Response Faster With Abrocitinib Compared to Dupilumab Itch Response Faster With Abrocitinib Compared to Dupilumab

An experimental oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, showed greater itch reduction after 2 weeks of treatment than dupilumab in patients with moderate to severe atopic dermatitis, in a multicenter, randomized trial.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news